Here’s What RBC Capital Has to Say About Verastem (VSTM)

Verastem, Inc. (NASDAQ:VSTM) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 24, RBC Capital reiterated an Outperform rating on Verastem, Inc. (NASDAQ:VSTM) with a $15 price target. The firm noted that the bullish sentiment is based on the company’s G12D inhibitor drug program.

​The firm noted that the G12D inhibitor program targets a specific genetic mutation found in certain cancers, and this is an important area of competitive drug development. The firm noted that they remain reassured on the drug’s efficacy and expect the results seen in patients outside the US to reasonably translate to US patients across the drug’s major target indications.

​In terms of the safety profile, the firm sees some room for improvement, but overall sees the drug as market competitive. The update was based on early, preliminary Phase 1/2 data and safety data rather than full efficacy results. RBC expects a more complete data readout with longer patient follow-up in the second half of 2026.

Verastem Inc. (NASDAQ:VSTM) is a biopharmaceutical company that develops and commercializes new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.